Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: GlobeNewswire
CHICAGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing transformative therapies for patients with rare and life-threatening diseases, today announced the appointment of Dr. Shaad Abedin as Chief Medical Officer. Dr. Abedin brings to Quetzal extensive experience in oncology drug development, translational medicine, biomarker strategy, and business development. He has a proven track record of advancing groundbreaking therapies across multiple modalities and leading clinical programs from early development through global regulatory approvals. Most recently, Dr. Abedin served as Senior Vice President and Head of Clinical Development at iTeos Therapeutics, where he oversaw clinical development and clinical pharmacology for a pipeline spanning both small- and large-molecule programs. Prior to iTeos, he held senior leadership roles at CARsgen and Immunocore, where he directed the clinical development of tebentafusp (KIMMTRA
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore (IMCR) Q2 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for "Best Bridge-Builder Institution," "Best Biomedical Product," "Best Medical Technology/AI Advances in Human Health," "Best Product for Rare/Orphan Diseases," and "Best Public SecPR Newswire
- Immunocore (NASDAQ:IMCR) had its price target raised by analysts at Morgan Stanley from $34.00 to $36.00. They now have an "equal weight" rating on the stock.MarketBeat
- Immunocore to present at upcoming investor conferencesGlobeNewswire
- Immunocore Holdings plc (NASDAQ:IMCR) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/25 - Beat
IMCR
Sec Filings
- 12/1/25 - Form 4
- 11/28/25 - Form 8-K
- 11/26/25 - Form 4
- IMCR's page on the SEC website